Browsing Tag
Type 2 Inflammation
2 posts
What KT‑621 success could mean for oral immunology drugs and Kymera Therapeutics
Get ready for Kymera Therapeutics' KT‑621 Phase 1b data on December 8. Can this oral eczema drug change the future of immunology?
Dupixent receives FDA approval for treatment of moderate-to-severe asthma
Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration…